Microsulis microwave ablation system approved to show ETL safety mark

7 November 2011

Microsulis Medical Ltd has received approval to apply the ETL safety mark to its Acculis microwave tissue ablation (MTA) system. The company says the system has already been successfully commercialised in Europe and North America, and is now being rolled out to the rest of the world.

The ETL Mark independently verifies compliance with international safety standards, and is recognised world-wide. This accreditation mark will now appear on Microsulis Medical’s Sulis VpMTA Generator, which powers the Acculis range of microwave tissue ablation devices.

Stuart McIntyre, Microsulis Medical’s Chief Executive, said: “We are pleased to apply this standard to our products. The ETL mark is a trusted accreditation, which will underpin commercialisation of our innovative technology in emerging markets.”

Microsulis Medical specialises in minimally invasive, soft tissue ablation devices utilising microwave technology. The company’s leading product is the Accu2i pMTA applicator, which is a needle-like device that has been used by clinicians to treat tumours of the liver, lung, kidneys and bone.

This device was CE-marked in February 2010, FDA 510(k) cleared in August 2010, approved for use in Australia and New Zealand in August 2010, and gained a Health Canada licence in January 2011.

Source: Microsulis Medical


To top